SecBot SecBot
PRESS-RELEASE ·Filed May 18, 2026

WVE

Wave Life Sciences USA, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong clinical data for WVE-006 de-risks the program and supports accelerated approval potential. Traders should monitor for FDA feedback mid-2026 and additional data from the 600 mg monthly cohort in H2 2026. The stock may re-rate upward on the back of this catalyst.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.14
T+0 close · May 18, 2026 · via day close
Latest settled
−15.31%
T+60 · $5.20
Vs SPY
−21.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $6.14entry
  2. T+1 · 6mo ago +0.81%α −0.23% · $6.19
  3. T+5 · 6mo ago +4.80%α +2.56% · $6.44
  4. T+20 · 5mo ago −3.09%α −4.08% · $5.95
  5. T+60 · 3mo ago −15.31%α −21.60% · $5.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT to protective levels (64.4% of total, matching low-risk MZ phenotype), reduction of toxic Z-AAT by up to 70.5%, and restored dynamic AAT production during acute phase responses. The drug was well-tolerated with monthly subcutaneous dosing, supporting a potential best-in-class profile. The company expects FDA feedback on an accelerated approval pathway mid-2026.

Key Facts

  • WVE-006 restored wild-type M-AAT to 64.4% of total AAT, matching heterozygous MZ individuals with low disease risk.
  • Treatment reduced harmful Z-AAT by up to 70.5% (200 mg biweekly multiple doses).
  • Total AAT reached 11.9 µM (200 mg biweekly) and 13.6 µM (400 mg monthly).
  • Dynamic AAT production was restored, with three instances of acute phase response-driven AAT elevation.
  • WVE-006 was generally safe and well-tolerated, with no serious adverse events or liver toxicities.
  • Wave expects FDA feedback on a potential accelerated approval pathway mid-2026.

Financial Impact

Significant positive impact on stock valuation; AATD market represents billions in annual sales potential.

market cap

Risk Factors

  • Regulatory risk: FDA may not agree to accelerated approval pathway.
  • Clinical risk: longer-term safety and efficacy data still needed.
  • Competitive risk: existing augmentation therapy and other pipeline candidates.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3297034

Track record

16 reports on WVE

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
  2. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
  3. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  4. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  5. Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  6. Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
  7. Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
  8. Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
  9. May 18, 202626w ago Press Release Bullish 7/10 Viewing Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
  10. Apr 28, 202628w ago 8-K Bullish 7/10 No price data
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026